Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Initial coagulation markers in patients with visceral leishmaniasis treated with tranexamic acid
RBR-6xbgv9jNot yet recruiting
- Sponsor
- Instituto de Doenças Tropicais Natan Portela
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in visceral leishmaniasis (VL) comparing Tranexamic acid with Normal saline placebo control (2 arms). Primary endpoint: Coagulation and fibrinolysis markers. Planned start May 2023; status: not yet recruiting.
02
Drugs
tranexamic acid
03
Conditions
visceral leishmaniasis (VL)
Beyond the preview
Go deeper on RBR-6xbgv9j.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-6xbgv9j.